阿托伐他汀对老年心力衰竭合并低骨量患者心肌纤维化及骨量、肌力的影响

Abstract
Figure/Table
References (27)
Related Citation (15)

Download: PDF (596 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To investigate the effect of Atorvastatin on myocardial fibrosis, bone mass and muscle strength in elderly patients with heart failure complicated with low bone mass. Methods A total of 100 elderly patients with heart failure complicated with low bone mass who were admitted to the Third People’s Hospital of Bengbu Affiliated to Bengbu Medical College from September 2019 to June 2020 were selected as the research subjects, and they were divided into group A and group B according to random number table method, with 50 patients in each group. Group A was treated with conventional treatment, and group B was treated with Atorvastatin on the basis of group A. Both groups were treated for three months. The changes of myocardial fibrosis, bone mass and muscle strength before and after treatment were compared between the two groups, and the incidence of adverse reactions between the two groups was counted. Results There were no significant differences in the levels of type Ⅰ procollagen (PC Ⅰ), type Ⅲ procollagen (PC Ⅲ), laminin (LN) and hyaluronic acid (HA) between the two groups before treatment (P ＞ 0.05). After treatment, the levels of PC Ⅰ, PC Ⅲ, LN and HA in both groups were lower than those before treatment, and group B was lower than group A, the differences were statistically significant (all P ＜ 0.05). The changes of bone mineral density of lumbar anterior position L1-4, femoral neck and hip in group B were higher than those in group A, and the differences were statistically significant (all P ＜ 0.05). There were no significant differences in the change of left and right hand grip strength and the total incidence of adverse reactions between the two groups (P ＞ 0.05). Conclusion Atorvastatin treatment for elderly patients with heart failure complicated with low bone mass can effectively inhibit myocardial fibrosis and promote bone formation, but it has no obvious effect on muscle strength and has good safety.

Key words： Atorvastatin Heart failure Low bone mass Myocardial fibrosis Bone mass Muscle strength

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	DENG Liwen SANG Gengsheng▲

Cite this article:

DENG Liwen SANG Gengsheng▲. Effect of Atorvastatin on myocardial fibrosis, bone mass and muscle strength in elderly patients with heart failure complicated with low bone mass[J]. 中国医药导报, 2021, 18(11): 54-57.

URL:

https://www.yiyaodaobao.com.cn/EN/ OR https://www.yiyaodaobao.com.cn/EN/Y2021/V18/I11/54

1] 中华医学会放射学分会骨关节学组，中国医师协会放射医师分会肌骨学组，中华医学会骨科学分会骨质疏松学组，等.骨质疏松的影像学与骨密度诊断专家共识[J].中国骨与关节杂志，2020，9（9）：666-673.
[2] 刘菊香，刘静.基层医生应重视骨质疏松症的防治[J].中华全科医师杂志，2020，19（4）：290-292.
[3] Jacobs D，Wassell K，Guidry TJ，et al. Safety Outcomes of Atorvastatin 80 mg Versus Atorvastatin 40 mg in a Veteran Population [J]. Ann Pharmacother，2020，54（2）：151-156.
[4] 陈渝春，俸家富，杨渝伟.两种他汀类药物治疗心血管病风险患者对血小板体积的影响[J].四川医学，2020，41（1）：66-71.
[5] 陈仕毅，陈晓茹，刘羽，等.阿托伐他汀对大鼠心肌梗死后心肌纤维化的干预作用[J].中国循证心血管医学杂志，2020，12（5）：616-619.
[6] 王璐，王男，梁昆.瑞舒伐他汀与阿托伐他汀对急性心肌梗死患者心肌纤维化干预的对照研究[J].药物评价研究，2019，42（5）：907-911.
[7] Kristiansen O，Vethe NT，Fagerland MW，et al. A novel direct method to determine adherence to atorvastatin therapy in patients with coronary heart disease [J]. Br J Clin Pharmacol，2019，85（12）：2878-2885.
[8] 沈建中，田然，甄俊峰等.他汀类药物治疗老年冠心病的安全性研究[J].中国循证心血管医学杂志，2018，10（6）：723-725.
[9] 朱晓红，梁菊红，杨青娟，等.阿托伐他汀钙与低剂量雌激素联合治疗围绝经期女性骨质疏松的临床效果[J].贵州医药，2019，43（3）：395-396.
[10] 中华医学会心血管病学分会心力衰竭学组，中国医师协会心力衰竭专业委员会中华心血管病杂志编辑委员会.中国心力衰竭诊断和治疗指南2018[J].中华心血管病杂志，2018，46（10）：760-789.
[11] Bing R，Cavalcante JL，Everett RJ，et al. Imaging and Impact of Myocardial Fibrosis in Aortic Stenosis [J]. JACC Cardiovasc Imaging，2019，12（2）：283-296.
[12] Yang J，Li Y，Li Y，et al. Effects of atorvastatin on pharmacokinetics of amlodipine in rats and its potential mechanism [J]. Xenobiotica，2020，50（6）：685-688.
[13] Oztas M，Ugurlu S，Aydin O. Atorvastatin-induced dermatomyositis [J]. Rheumatol Int，2018，37（7）：1217-1219.
[14] 翟原生，李杰，卢贵华，等.阿托伐他汀对心室重塑和心肌AVP、TGF-β1的影响[J].中山大学学报：医学科学版，2020，41（3）：436-444.
[15] 李铭扬，桑明，孙晓东，等.阿托伐他汀对大鼠心肌梗死后p38磷酸化及心脏重构的影响[J].华中科技大学学报：医学版，2018，47（3）：280-285.
[16] 王璐，王男，梁昆.瑞舒伐他汀与阿托伐他汀对急性心肌梗死患者心肌纤维化干预的对照研究[J].药物评价研究，2019，42（5）：907-911.
[17] Yuan L，Kenny SJ，Hemmati J，et al. TANGO1 and SEC12 are copackaged with procollagen I to facilitate the generation of large COPII carriers [J]. Proc Natl Acad Sci U S A，2018，115（52）：E12255-E12264.
[18] 荣鸽璇，李昕玲，谭弘，等.生脉饮联合依那普利治疗慢性心力衰竭的临床研究[J].现代药物与临床，2019，34（6）：1657-1661.
[19] 李崇耀，张曼，赵鸿斌，等.沙库巴曲缬沙坦联合芪苈强心胶囊治疗慢性心力衰竭患者的临床疗效观察[J].疑难病杂志，2020，19（7）：667-671.
[20] 唐金莉，李杰.参附注射液对缺血性心肌病伴急性心力衰竭患者心功能和心肌纤维化的影响[J].世界中医药，2018，13（9）：103-105.
[21] 刘颖，李争，张玉焕，等.芪参益气汤联合厄贝沙坦治疗老年慢性心力衰竭临床观察[J].西部中医药，2020，33（6）：98-101.
[22] 陈莹.心肌纤维化血清学指标对优化心功能分级及预测心力衰竭预后的临床意义[J].岭南心血管病杂志，2018， 24（2）：189-192.
[23] 张驰，王珣，王丽岳，等.葛根素联合阿托伐他汀对2型糖尿病心肌病大鼠脂联素、炎症因子及心肌纤维化的影响[J].现代中西医结合杂志，2020，29（11）：1167-1171.
[24] 李晓琳，刘永欣.阿托伐他汀对急性心肌梗死大鼠心肌炎症及纤维化反应Notch1信号通路、转化生长因子-β的影响[J].安徽医药，2020，24（3）：429-432.
[25] 张慧阁，郑荣果，任红欣.阿托伐他汀逆转原发性高血压患者左心室心肌肥厚临床研究[J].中国药业，2018， 27（24）：71-73.
[26] 苏晓.阿仑膦酸钠联合阿托伐他汀对糖尿病合并骨质疏松患者骨密度及骨代谢水平的影响[J].山西医药杂志，2019，48（22）：2769-2771.
[27] 王小冬，杜艳萍，肖峰，等.阿托伐他汀对老年高胆固醇血症合并低骨量患者骨量和肌力的作用效果研究[J].中国全科医学，2020，23（21）：2669-2672.